Last reviewed · How we verify
ARV-110
Selective androgen receptor degrader
Selective androgen receptor degrader Used for Prostate cancer.
At a glance
| Generic name | ARV-110 |
|---|---|
| Sponsor | Arvinas Inc. |
| Drug class | Selective androgen receptor degrader |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ARV-110 is a selective androgen receptor degrader (SARD) that targets the androgen receptor (AR) for degradation, leading to a decrease in androgen receptor-mediated signaling.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Muscle spasm
- Diarrhea
Key clinical trials
- Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PHASE1)
- Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARV-110 CI brief — competitive landscape report
- ARV-110 updates RSS · CI watch RSS
- Arvinas Inc. portfolio CI